Articles by Daniel Marsh
NNBR Surges on NVIDIA Liquid-Cooling Contracts; Trading Volume Explodes
NNBR shares surged 39.47% on heavy volume after announcing new liquid-cooling contracts for NVIDIA AI data centers. Trading volume hit 56 million shares, well above the public float.
Surf Air Mobility Soars on Palantir Deal, Dilution Concerns Loom
Surf Air Mobility shares jumped 17.5% after Palantir expanded their SurfOS partnership, but heavy trading volume and dilution from a stock-for-services deal are key concerns.
SoFi Technologies Surges in Premarket on Heavy Trading Volume
SoFi Technologies (SOFI) climbed 1.29% in Monday's premarket, following a surge in trading volume that reached 90.63 million shares on Friday.
Plug Power Faces Key Cash Deadline as Short Interest Swells
Plug Power (PLUG) shares gain 1.6% in premarket ahead of a critical June 30 asset sale deadline, as short interest remains elevated at 25.5% of the public float.
Volato Group Issues Shares at Steep Discount, Dilution Looms
Volato Group is selling 11.04 million shares at $0.165 each, a steep discount to its recent PIPE, raising $1.82 million and diluting existing shareholders by over 53%.
Keel Infrastructure Gains Premarket Following Russell 3000 Inclusion
Keel Infrastructure shares climbed 2.24% in premarket trading after being added to the Russell 3000 Index, following Friday's massive 122.41 million share volume.
Lucid Stock Rises on Cost-Cutting Plan as Delivery Deadline Looms
Lucid (LCID) shares rose pre-market after unveiling a $158M cost-cut plan, about 8.1% of its market cap, as a June 30 delivery deadline for U.S. promotions approaches, putting demand to the test.
Southwest Airlines Trims St. Louis Routes, Shifts Focus to Higher-Yield Markets
Southwest Airlines is cutting seven St. Louis route pairs for Q3 2026, trimming local seats by 8% and reducing airport share to 61% as part of a broader strategy to enhance unit revenue.
Moderna Stock Surges Past Analyst Targets Ahead of FDA Flu Vaccine Decision
Moderna shares surged over 12% Friday to $67.27, now trading above most Wall Street targets ahead of an FDA decision on its mRNA flu vaccine.


